ArticleNucleic acids research2026
Metabolic isotopic labeling of (deoxy)ribose enables dual neutral loss scanning for profiling nucleic acid modifications.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Modifications on DNA and RNA, even at trace levels, play critical roles in diverse biological processes, yet their accurate quantification and discovery of novel modified constituents remain challenging. Here, we present a metabolic (deoxy)ribose-labeling approach integrated with multiple reaction monitoring mass spectrometry (MRM-MS) to enable sensitive and untargeted detection of nucleic acid modifications. In this approach, [U-13C]glucose is used to generate an ∼1:1 ratio of ¹³C5-labeled and unlabeled deoxyribose moieties in vivo, followed by MRM-MS acquisition of neutral-loss transitions corresponding to both isotopic forms. This isotopic pairing facilitates the differentiation of endogenous nucleosides from contaminants and allows confident assignment of authentic nucleoside signals. Applying this method to mouse embryonic stem cells, we detected rare nucleoside species such as 5-formylcytosine and 5-carboxycytosine, present at frequencies as low as one in 106-107 bases. In contrast, peaks assigned to N6-methyladenine (6mA) lacked a labeled counterpart, suggesting that previously reported 6mA in mammalian DNA may arise from RNA misincorporation or artifacts introduced during the processing of isolated DNA. Analysis of formaldehyde-treated DNA revealed several previously unreported adducts, including N4-hydroxymethyl-5-hydroxymethylcytosine (4hm5hmC, or dihmC). Collectively, this (deoxy)ribose-labeling strategy provides a robust and sensitive platform for untargeted nucleoside profiling and the discovery of uncharacterized nucleic acid modifications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.